| Effects of carfilzomib therapy on left ventricular function in multiple myeloma patients G Mingrone, A Astarita, L Airale, I Maffei, M Cesareo, T Crea, G Bruno, ... Frontiers in Cardiovascular Medicine 8, 645678, 2021 | 10 | 2021 |
| Multiple myeloma patients undergoing carfilzomib: development and validation of a risk score for cardiovascular adverse events prediction A Astarita, G Mingrone, L Airale, F Vallelonga, M Covella, C Catarinella, ... Cancers 13 (7), 1631, 2021 | 10 | 2021 |
| Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma M D’Agostino, G Gazzera, G Cetani, S Bringhen, M Boccadoro, F Gay Current Medicinal Chemistry 26 (32), 5968-5981, 2019 | 8 | 2019 |
| A look at treatment strategies for relapsed multiple myeloma G Cetani, M Boccadoro, S Oliva Expert review of anticancer therapy 18 (8), 735-750, 2018 | 5 | 2018 |
| On-demand plerixafor with cyclophosphamide and G-CSF for hematopoietic stem-cell mobilization in multiple myeloma patients: preliminary results of a prospective observational … R Mina, F Bonello, G Milone, MT Petrucci, C Nozzoli, V Bongarzoni, ... Blood 136, 13-14, 2020 | 4 | 2020 |
| Efficacy and safety of ixazomib induction and maintenance in newly diagnosed multiple myeloma patients according to the IMWG frailty score: A post-hoc analysis of the EMN10 … R Mina, A Larocca, M Offidani, V Innao, C Cellini, M Galli, G Cetani, ... Blood 136, 44-45, 2020 | 4 | 2020 |
| Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation V Apolito, L Giaccone, S Ferrero, A Larocca, F Cavallo, M Coscia, ... Annals of Hematology 99, 2197-2199, 2020 | 4 | 2020 |
| Moving toward continuous therapy in multiple myeloma F Bonello, G Cetani, L Bertamini, F Gay, A Larocca Clinical Hematology International 1 (4), 189-200, 2019 | 4 | 2019 |
| Safety of subcutaneous daratumumab in anti-CD38 monoclonal antibody-naive patients with plasma cell disorders: a multicenter real-life experience D De Novellis, R Fontana, S Palmieri, R Della Pepa, M Di Perna, G Cetani, ... Targeted Oncology 18 (6), 885-892, 2023 | 1 | 2023 |
| Bortezomib-dexamethasone Re-treatment at biochemical relapse vs observation in relapsed/refractory multiple myeloma patients: results of a phase II multi-center, randomized study R Mina, A Larocca, A Belotti, F Di Raimondo, A Baraldi, M Offidani, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 3128 …, 2017 | 1 | 2017 |
| Netupitant-palonosetron (NEPA) to Prevent Chemotherapy-induced Nausea and Vomiting (CINV) in Multiple Mieloma (MM) Patients Receiving High-Dose (HD) Melphalan and Autologous … V Apolito, S Ferrero, M D'Agostino, G Cetani, F Bonello, F Martella, ... BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 624-625, 2020 | | 2020 |
| CLONAL EVOLUTION AFTER THERAPY REVEALED BY LONGITUDINAL CHROMOSOMAL ABNORMALITIES IN MULTIPLE MYELOMA DISEASE PROGRESSION S Caltagirone, S Oliva, M Ruggeri, G Cetani, S Spada, D Oddolo, R Troia, ... HAEMATOLOGICA 103, S82-S82, 2018 | | 2018 |
| Pain management in multiple myeloma M Salvini, G Cetani Expert Review of Quality of Life in Cancer Care 3 (1), 9-18, 2018 | | 2018 |
| Correlazione tra dati istologici e profili immunofenotipici in pazienti affetti da mieloma multiplo in differente tipo di trattamento G Cetani, G Carulli, G Buda, N Cecconi, EM Ciancia, P Sammuri, ... BioMedia Centro Convegni 41 (1), 72, 2017 | | 2017 |
| Correlation between bone marrow histology and plasma cell immunophenotyping in patients with multiple myeloma under various treatments G Cetani, G Carulli, G Buda, N Cecconi, EM Ciancia, P Sammuri, ... BIOCHIMICA CLINICA 41 (1), 72-78, 2017 | | 2017 |
| Correlazione tra dati istologici e profili immunofenotipici in pazienti affetti da Mieloma Multiplo, sottoposti a chemioterapia e trapianto di midollo G CETANI | | 2015 |
| DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE G Cetani | | |
